IP Library Granted Patent US 9,855,427
Granted Patent B2
US 9,855,427 · App. 15/453,978 · Granted Jan 2, 2018

Systems and methods for the treatment of pain through neural fiber stimulation

Inventors: Maria E. Bennett (Beachwood, OH); Joseph W. Boggs (Chapel Hill, NC); Warren M. Grill (Chapel Hill, NC); John Chae (Strongsville, OH)
Assignee: SPR THERAPEUTICS, INC.
A61N1/36071A61N1/36003A61N1/36017A61N1/36021A61N1/36057
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,855,427
App. No.
15/453,978
Granted
Jan 2, 2018
Kind
B2
Abstract

Embodiments of the present invention provide systems and methods for the treatment of pain through activation of select neural fibers. The neural fibers may comprise one or more afferent neural fibers and/or one or more efferent neural fibers. If afferent fibers are stimulated, alone or in combination with efferent fibers, a therapeutically effective amount of electrical stimulation is applied to activate afferent pathways in a manner approximating natural afferent activity. The afferent fibers may be associated with primary receptors of muscle spindles, golgi tendon organs, secondary receptors of muscle spindles, joint receptors, touch receptors, and other types of mechanoreceptors and/or proprioceptors. If efferent fibers are stimulated, alone or in combination with afferent fibers, a therapeutically effective amount of electrical stimulation is applied to activate intrafusal and/or extrafusal muscle fibers, which results in an indirect activation of afferent fibers associated therewith.

Claims (36)

1. A method of reducing a perception of pain, the method comprising the steps of:

percutaneously inserting a single contact electrode operatively coupled with a lead in-vivo in a patient a therapeutically effective distance from a target efferent nerve fiber;

electrically stimulating through the lead and electrode the target efferent nerve fiber to generate an action potential in the target efferent nerve fiber while avoiding generation of action potentials in a small sensory nerve fiber to generate a reduction of pain in the patient.

2. The method of claim 1 , wherein the therapeutically effective distance is 1 mm from the target afferent nerve fiber.

3. The method of claim 1 , wherein the target efferent nerve fiber is located between a neurological motor point and the central nervous system of the patient.

4. The method of claim 1 , wherein the generation of action potentials in the small sensory nerve fiber comprises generation of action potentials in Type III and Type IV nerve fibers.

5. The method of claim 1 , wherein the target efferent nerve fibers comprise motor axons.

6. The method of claim 5 , wherein the motor axons comprise Act axons.

7. The method of claim 1 , wherein the target efferent nerve fiber is located within a region of pain.

8. The method of claim 1 , wherein the target efferent nerve fiber is located outside of a region of pain.

9. A method of reducing a perception of pain, the method comprising the steps of:

percutaneously inserting a lead into a patient, the lead having an electrode extending therefrom, wherein the electrode is positioned at a therapeutically effective distance from a target motor axon;

electrically stimulating through the electrode the target motor axon to generate an action potential in the target motor axon while avoiding generation of action potentials in Type III and Type IV afferent nerve fibers; and

removing the lead and electrode, wherein pain relief is generally maintained for a time after the removal.

10. The method of claim 9 , wherein the electrode is a single contact electrode.

11. The method of claim 9 , wherein the electrical stimulation relieves pain.

12. The method of claim 9 , wherein the time is two weeks.

13. The method of claim 9 , wherein the motor axon comprises an Aα axon.

14. The method of claim 9 , wherein the motor axon comprises an Aγ axon.

15. A method of reducing a perception of pain, the method comprising:

percutaneously inserting a lead having a single contact electrode into a patient; and

electrically stimulating through the single contact electrode inserted in-vivo by an electrical stimulator a plurality of target efferent motor nerve fibers to generate an action potential in the plurality of target efferent motor nerve fibers while avoiding generation of action potentials in small sensory nerve fibers.

16. The method of claim 15 , wherein the small sensory nerve fibers include Type III and IV nerve fibers.

17. The method of claim 15 , wherein the electrode is inserted a therapeutically effective distance from the target efferent motor nerve fibers, whereby the therapeutically effective distance is 1 mm from the target efferent motor nerve fibers.

18. The method of claim 15 , wherein generating the action potential in the plurality of target efferent motor nerve fibers causes a contraction of muscle.

19. The method of claim 18 , wherein the contraction of muscle reduces the perception of pain.

20. A system to reduce a perception of pain, the system comprising:

a lead;

a single contact electrode operatively coupled with the lead, the electrode percutaneously inserted into a patient; and

an electrical stimulator operatively coupled with the lead, the electrical stimulator electrically stimulating through the single contact electrode a plurality of target efferent motor nerve fibers to generate an action potential in the plurality of target efferent motor nerve fibers while avoiding generation of action potentials in small sensory nerve fibers.

21. The system of claim 20 , wherein generation of action potentials in the small sensory nerve fibers causes contraction of muscle.

22. The system of claim 21 , wherein the contraction of muscle reduces the perception of pain.

23. A system to reduce a perception of pain, the system comprising:

a percutaneous lead;

a single contact electrode operatively coupled with the percutaneous lead, the electrode placed in at least one of muscle, subcutaneous, connective or adipose tissue located near a nerve trunk upstream from a region of pain;

an electrical stimulator operatively coupled with the lead, the electrical stimulator electrically stimulating through the single contact electrode a plurality of target efferent motor nerve fibers to generate an action potential in the plurality of target efferent motor nerve fibers while avoiding generation of action potentials in small sensory nerve fibers.

Assignments (9)
RELEASE OF SECURITY INTEREST Recorded Feb 8, 2024
From: THE DIRECTOR OF DEVELOPMENT, STATE OF OHIO, FORMERLY KNOWN AS THE DIRECTOR OF THE OHIO DEVELOPMENT SERVICES AGENCY
To: SPR THERAPEUTICS, INC., FORMERLY KNOWN AS SPR THERAPEUTICS, LLC
Reel/Frame 066526/0025 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jan 30, 2024
From: SPR THERAPEUTICS, INC.
To: SLR INVESTMENT CORP., AS AGENT
Reel/Frame 066381/0075 →
SECURITY INTEREST Recorded Jan 30, 2024
From: SPR THERAPEUTICS, INC.
To: GEMINO HEALTHCARE FINANCE, LLC
Reel/Frame 066412/0400 →
RELEASE OF SECURITY INTEREST Recorded Oct 15, 2019
From: THE DIRECTOR OF THE OHIO DEVELOPMENT SERVICES AGENCY
To: SPR THERAPEUTICS, INC.
Reel/Frame 050728/0676 →
RELEASE OF SECURITY INTEREST Recorded Oct 15, 2019
From: THE DIRECTOR OF THE OHIO DEVELOPMENT SERVICES AGENCY
To: SPR THERAPEUTICS, INC.
Reel/Frame 050728/0721 →
CHANGE OF NAME Recorded Dec 6, 2017
From: SPR THERAPEUTICS, LLC
To: SPR THERAPEUTICS, INC.
Reel/Frame 044716/0812 →
SECURITY INTEREST Recorded Nov 9, 2017
From: SPR THERAPEUTICS, INC.
To: THE DIRECTOR OF THE OHIO DEVELOPMENT SERVICES AGENCY
Reel/Frame 044414/0575 →
SECURITY INTEREST Recorded Nov 9, 2017
From: SPR THERAPEUTICS, INC.
To: THE DIRECTOR OF THE OHIO DEVELOPMENT SERVICES AGENCY
Reel/Frame 044715/0395 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 9, 2017
From: BENNETT, MARIA E.; BOGGS, JOSEPH W.; GRILL, WARREN M.; CHAE, JOHN
To: SPR THERAPEUTICS, LLC
Reel/Frame 041518/0938 →
Continuity (7)
Continuation 14336633 · Jul 21, 2014
Continuation 13309024 · Dec 1, 2011
Continuation In Part 13294875 · Nov 11, 2011
Provisional Application 61418801 · Dec 1, 2010
Provisional Application 61418768 · Dec 1, 2010
Provisional Application 61412685 · Nov 11, 2010
Related Publication 20170173337A1 · Jun 22, 2017